|
| Press Releases |
|
|
| Thursday, May 31, 2018 |
|
|
卓珈控股公布2017/2018财政年度全年业绩 纯利录得26.5百万港元 |
| 香港的医学美容服务供应商卓珈控股集团有限公司（「卓珈控股」或「集团」；股份代号：8358）今天公布2017/2018财政年度全年业绩。 more info >> |
|
|
卓珈控股公佈2017/2018財政年度全年業績 純利錄得26.5百萬港元 |
| 香港的醫學美容服務供應商卓珈控股集團有限公司（「卓珈控股」或「集團」；股份代號：8358）今天公佈2017/2018財政年度全年業績。 more info >> |
|
|
Miricor Announces FY2017/2018 Annual Results; Records Net Profit of HK$26.5 Million |
| Miricor Enterprises Holdings Limited ("Miricor" or the "Group", stock code: 8358), a medical aesthetic services provider in Hong Kong, has today announced its annual results for FY2017/2018. more info >> |
|
| Friday, August 11, 2017 |
|
|
卓珈控股公佈2017/2018財政年度第一季業績 |
| 香港醫學美容服務供應商卓珈控股集團有限公司（「卓珈控股」或「集團」；股份代號：8358），今天公佈2017/2018財政年度未經審核之第一季業績。 more info >> |
|
|
Miricor Announces FY2017/2018 First Quarterly Results |
Miricor Enterprises Holdings Limited ("Miricor" or the "Group", stock code: 8358), a medical aesthetic service provider in Hong Kong, has today announced its unaudited first quarter financial results for FY2017/2018.
more info >> |
|
| Monday, February 13, 2017 |
|
|
卓珈控股公佈2016/17財政年度第三季業績，收益增加21.9%至74.5百萬港元 |
香港的醫學美容服務供應商卓珈控股集團有限公司（「卓珈控股」或「集團」；股份代號：8358），今天公佈2016/17財政年度第三季業績，其於2017年1月10日在香港聯合交易所有限公司成功上市。
more info >> |
|
|
Miricor Announces FY2016/17 Third Quarterly Results; Revenue up 21.9% to HK$74.5 Million |
Miricor Enterprises Holdings Limited ("Miricor" or the "Group", stock code: 8358), a medical aesthetic service provider in Hong Kong, today announced its third quarterly results of FY2016/17 after its successful listing on The Stock Exchange of Hong Kong Limited on 10 January 2017.
more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
playX Secures Industry-Leading Player Protection Through Landmark Insurance Partnership with Great American Insurance Group
Feb 8, 2026 23:30: JST
|
|
|
playX Secures Industry-Leading Player Protection Through Landmark Insurance Partnership with Great American Insurance Group
Feb 8, 2026 23:30 HKT/SGT
|
|
|
Mr Liu Xiaojun, on behalf of Fufeng Group, has fully completed the acquisition of Viva World Trade, Inc.
Feb 7, 2026 05:45 HKT/SGT
|
|
|
GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China's Core Innovative Drug Assets
Feb 6, 2026 17:45 HKT/SGT
|
|
|
GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share
Feb 6, 2026 17:01 HKT/SGT
|
|
|
歌禮製藥-B（01672）獲新加坡政府投資公司首次入股 涉資約1億美元
Feb 6, 2026 16:56 HKT/SGT
|
|
|
歌礼制药-B（01672）获新加坡政府投资公司首次入股 涉资约1亿美元
Feb 6, 2026 16:50 HKT/SGT
|
|
|
COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization
Feb 6, 2026 16:34 HKT/SGT
|
|
|
トヨタ、役員人事を発表
Feb 6, 2026 16:00: JST
|
|
|
牧原股份港股上市：全球生豬养殖龍頭 價值成長兼具
Feb 6, 2026 15:08 HKT/SGT
|
|
|
牧原股份港股上市：全球生猪养殖龙头 价值成长兼具
Feb 6, 2026 15:01 HKT/SGT
|
|
|
優異供應鏈賦能與國際化佈局雙輪驅動 綠茶開啟高質量成長新篇章
Feb 6, 2026 14:47 HKT/SGT
|
|
|
优异供应链赋能与国际化布局双轮驱动 绿茶开启高质量成长新篇章
Feb 6, 2026 14:33 HKT/SGT
|
|
|
Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis
Feb 6, 2026 14:17 HKT/SGT
|
|
|
雲頂新耀維適平(R)獲中國國家藥品監督管理局批准上市 為中重度潰瘍性結腸炎治療提供新選擇
Feb 6, 2026 14:11 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
